Theralase Technologies Inc. (TSXV: TLT; OTCQB: TLTFF) has closed a brokered private placement that raised gross proceeds of C$3.555 million, providing additional capital for its cancer and antiviral development programs.
According to the August 24 announcement, Theralase issued 14,812,500 units at C$0.24 per unit. Each unit contains one common share and one warrant exercisable at C$0.32 until May 20, 2031.
Research Capital Corporation acted as the sole agent and bookrunner. Theralase paid a cash commission of C$216,893 and issued 903,723 compensation options. The financing remains subject to final acceptance by the TSX Venture Exchange.
The company intends to use the proceeds for Good Laboratory Practice toxicology studies supporting intravenous Rutherrin, a combination of Ruvidar and transferrin, in multiple cancer indications. Funding is also earmarked for further toxicology work involving topical Ruvidar for herpes simplex virus-related cold sores, along with working capital and general corporate expenses.
The completed financing was within the C$3 million-to-C$5 million range outlined when the offering was announced on August 10. Theralase has received conditional approval to list the newly issued warrants under the symbol TLT.WT and expects trading to begin on or around August 27, subject to final exchange approval.
Theralase President and CEO Roger DuMoulin-White said the company has “successfully raised approximately C$11,000,000 in equity and C$1,000,000 in debt” during the past eight months. Management plans to use its strengthened balance sheet to advance regulatory and development work during 2026 and 2027.
Theralase is separately completing follow-up assessments in its Phase 2 Study II of light-activated Ruvidar in patients with BCG-unresponsive non-muscle-invasive bladder cancer. In a February 2026 update, the company reported that 90 patients had been enrolled and treated, with 78 completing the study and 12 still pending completion at that time.
Upcoming Catalysts
- Expected listing of the TLT.WT warrants
- Remaining Study II patient follow-up assessments
- GLP toxicology work involving Rutherrin and topical Ruvidar
- Potential rolling-review submissions to Health Canada and the FDA
- Future regulatory decisions regarding Ruvidar for bladder cancer
Sources
- Theralase financing close — August 24, 2026, via Newsfile
- Original LIFE offering announcement — August 10, 2026, via Newsfile
- Theralase Study II update — February 4, 2026
Editorial Disclosure
This article is based entirely on publicly available information including press releases, SEC/SEDAR filings, and publicly available news sources. Securities discussed or referenced include Theralase Technologies Inc. (TSXV: TLT; OTCQB: TLTFF). Biotech Stocks Daily has not received any compensation from any company mentioned, their management, investor relations representatives, or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which does not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in any security mentioned at the time of publication.
Confirmed sources include Theralase press releases dated August 10 and August 24, 2026, distributed through Newsfile, and the company’s February 4, 2026 Study II update.
The financing remains subject to final TSXV acceptance. Issuance of 14,812,500 common shares resulted in shareholder dilution, while the accompanying warrants and compensation options could produce additional dilution if exercised. Ruvidar and Rutherrin remain investigational, and completion of development work, regulatory submissions or regulatory approvals is not assured. Clinical results cited by the company are interim results and may change as follow-up assessments are completed.
Financing figures are reported in Canadian dollars and are current as of August 24, 2026. Clinical figures reflect company disclosures dated February 4, 2026. No real-time securities prices are included, and readers should verify current figures independently.
These are speculative investments carrying significant risk including potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.
